# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TD Cowen analyst Max Masucci maintains Bruker (NASDAQ:BRKR) with a Hold and lowers the price target from $74 to $72.
The minority investment aims to accelerate the growth and further expansion of NovAliX, particularly within Europe and the Unit...
Bruker (NASDAQ:BRKR) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. The company repo...
Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Buy and lowers the price target from $95 to $80.
Goldman Sachs analyst Matthew Sykes maintains Bruker (NASDAQ:BRKR) with a Sell and lowers the price target from $72 to $60.
Based on cellular biophysical markers attained using Bruker's advanced atomic force microscopy, Cellens is developing its p...